Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Inhibiting inhibitory pathways in human γδ T cells.

Lopez RD.

Blood. 2013 Aug 8;122(6):857-8. doi: 10.1182/blood-2013-06-506584.

2.

The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.

Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult ML, Pastor S, Fitzgibbon J, Bouabdallah R, Xerri L, Olive D.

Blood. 2013 Aug 8;122(6):922-31. doi: 10.1182/blood-2012-11-464685. Epub 2013 May 21.

3.
4.

B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.

Hobo W, Norde WJ, Schaap N, Fredrix H, Maas F, Schellens K, Falkenburg JH, Korman AJ, Olive D, van der Voort R, Dolstra H.

J Immunol. 2012 Jul 1;189(1):39-49. doi: 10.4049/jimmunol.1102807. Epub 2012 May 25.

5.

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE.

J Clin Invest. 2010 Jan;120(1):157-67. doi: 10.1172/JCI40070. Epub 2009 Dec 28.

6.

Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.

Wrobel P, Shojaei H, Schittek B, Gieseler F, Wollenberg B, Kalthoff H, Kabelitz D, Wesch D.

Scand J Immunol. 2007 Aug-Sep;66(2-3):320-8.

7.

Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts.

Tao R, Wang L, Han R, Wang T, Ye Q, Honjo T, Murphy TL, Murphy KM, Hancock WW.

J Immunol. 2005 Nov 1;175(9):5774-82.

8.

Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?

Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O, Kummer JA.

Blood. 2002 Jan 1;99(1):232-7.

9.

B and T lymphocyte attenuator suppresses IL-21 production from follicular Th cells and subsequent humoral immune responses.

Kashiwakuma D, Suto A, Hiramatsu Y, Ikeda K, Takatori H, Suzuki K, Kagami S, Hirose K, Watanabe N, Iwamoto I, Nakajima H.

J Immunol. 2010 Sep 1;185(5):2730-6. doi: 10.4049/jimmunol.0903839. Epub 2010 Jul 26.

10.

Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells.

Harly C, Peyrat MA, Netzer S, Déchanet-Merville J, Bonneville M, Scotet E.

Blood. 2011 Mar 10;117(10):2864-73. doi: 10.1182/blood-2010-09-309781. Epub 2011 Jan 13.

11.

High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.

M'Hidi H, Thibult ML, Chetaille B, Rey F, Bouadallah R, Nicollas R, Olive D, Xerri L.

Am J Clin Pathol. 2009 Oct;132(4):589-96. doi: 10.1309/AJCPPHKGYYGGL39C.

PMID:
19762537
12.

CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.

Poccia F, Cipriani B, Vendetti S, Colizzi V, Poquet Y, Battistini L, López-Botet M, Fournié JJ, Gougeon ML.

J Immunol. 1997 Dec 15;159(12):6009-17.

PMID:
9550399
13.

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM.

Nat Immunol. 2003 Jul;4(7):670-9. Epub 2003 Jun 8.

PMID:
12796776
14.

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.

Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T, Molina T, Vekhoff A, Feugier P, Bouabdallah R, Birnbaum D, Olive D, Xerri L.

Blood. 2009 Mar 19;113(12):2765-3775. doi: 10.1182/blood-2008-07-168096. Epub 2008 Dec 18.

15.

The gp49B1 inhibitory receptor regulates the IFN-gamma responses of T cells and NK cells.

Gu X, Laouar A, Wan J, Daheshia M, Lieberman J, Yokoyama WM, Katz HR, Manjunath N.

J Immunol. 2003 Apr 15;170(8):4095-101.

16.

The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma.

Jones D, Fletcher CD, Pulford K, Shahsafaei A, Dorfman DM.

Blood. 1999 May 15;93(10):3487-93.

17.

Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells.

Wang XF, Chen YJ, Wang Q, Ge Y, Dai Q, Yang KF, Fang-Xie, Zhou YH, Hu YM, Mao YX, Zhang XG.

Tissue Antigens. 2007 Feb;69(2):145-53.

PMID:
17257317
18.

B- and T-lymphocyte attenuator targeting protects against the acute phase of graft versus host reaction by inhibiting donor anti-host cytotoxicity.

del Rio ML, Kurtz J, Perez-Martinez C, Ghosh A, Perez-Simon JA, Rodriguez-Barbosa JI.

Transplantation. 2011 Nov 27;92(10):1085-93. doi: 10.1097/TP.0b013e3182339d4a.

PMID:
21978997
19.

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.

Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, Murphy KM.

Nat Immunol. 2005 Jan;6(1):90-8. Epub 2004 Nov 28.

20.

Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity.

Fisch P, Meuer E, Pende D, Rothenfusser S, Viale O, Kock S, Ferrone S, Fradelizi D, Klein G, Moretta L, Rammensee HG, Boon T, Coulie P, van der Bruggen P.

Eur J Immunol. 1997 Dec;27(12):3368-79.

PMID:
9464825

Supplemental Content

Support Center